
CHMP approve Bristol-Myers Squibb’s Sprycel for paediatric patients with Ph+ ALL
pharmafile | December 17, 2018 | News story | Sales and Marketing | BMS, Bristol-Myers Squibb, Cancer, Sprycel, all
New Jersey-based firm Bristol -Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the expanded approval of Sprycel (dasatinib), in combination with chemotherapy for the treatment of paediatric patients (Ph+) acute lymphoblastic leukemia (ALL).
The powder form of Sprycel, which allows patients with an inability to swallow tablets to suspnd the medicines in water, was first approved by the European Commission in July 2018.
“We are pleased with today’s CHMP recommendation for Sprycel in pediatric patients with Ph+ ALL, and look forward to the possibility of expanding Sprycel’s pediatric indications in the EU to include young patients with this particularly high-risk leukemia,” said Fouad Namouni, M.D., head, oncology development, Bristol-Myers Squibb.
Louis Goss
Related Content

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer
Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination …

Central nervous system cancer metastases – the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds






